{"title":"胃食管腺癌的免疫疗法：管理现状如何？","authors":"Katherine M. Bever","doi":"10.1016/j.soi.2024.100099","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction and design</h3><div>This review summarizes clinical data available that supports the use of immune checkpoint inhibitors (ICIs) in the treatment of gastroesophageal adenocarcinoma (GEA). and current approvals as well as current and emerging biomarkers to guide patient selection for this approach. Included in this review is an assessment of clinical data in advanced/metastatic GEA and resectable GEA as well as biomarkers of response to ICIs in GEA, including mismatch repair deficiency, PDL1 expression, tumor mutation burden, and Epstein-Barr virus.</div></div><div><h3>Results and conclusion</h3><div>ICIs are active in GEA and both nivolumab and pembrolizumab are approved in in the front-line metastatic setting in combination with chemotherapy. Other ICIs are in development. Incorporation of ICI with chemotherapy appears to improve pathologic response rates in the resectable setting; however, longer term follow up is needed to confirm a survival benefit from this approach.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"1 4","pages":"Article 100099"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Immunotherapy in gastroesophageal adenocarcinoma: What is the state of management?\",\"authors\":\"Katherine M. Bever\",\"doi\":\"10.1016/j.soi.2024.100099\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction and design</h3><div>This review summarizes clinical data available that supports the use of immune checkpoint inhibitors (ICIs) in the treatment of gastroesophageal adenocarcinoma (GEA). and current approvals as well as current and emerging biomarkers to guide patient selection for this approach. Included in this review is an assessment of clinical data in advanced/metastatic GEA and resectable GEA as well as biomarkers of response to ICIs in GEA, including mismatch repair deficiency, PDL1 expression, tumor mutation burden, and Epstein-Barr virus.</div></div><div><h3>Results and conclusion</h3><div>ICIs are active in GEA and both nivolumab and pembrolizumab are approved in in the front-line metastatic setting in combination with chemotherapy. Other ICIs are in development. Incorporation of ICI with chemotherapy appears to improve pathologic response rates in the resectable setting; however, longer term follow up is needed to confirm a survival benefit from this approach.</div></div>\",\"PeriodicalId\":101191,\"journal\":{\"name\":\"Surgical Oncology Insight\",\"volume\":\"1 4\",\"pages\":\"Article 100099\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Surgical Oncology Insight\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2950247024001087\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Surgical Oncology Insight","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2950247024001087","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Immunotherapy in gastroesophageal adenocarcinoma: What is the state of management?
Introduction and design
This review summarizes clinical data available that supports the use of immune checkpoint inhibitors (ICIs) in the treatment of gastroesophageal adenocarcinoma (GEA). and current approvals as well as current and emerging biomarkers to guide patient selection for this approach. Included in this review is an assessment of clinical data in advanced/metastatic GEA and resectable GEA as well as biomarkers of response to ICIs in GEA, including mismatch repair deficiency, PDL1 expression, tumor mutation burden, and Epstein-Barr virus.
Results and conclusion
ICIs are active in GEA and both nivolumab and pembrolizumab are approved in in the front-line metastatic setting in combination with chemotherapy. Other ICIs are in development. Incorporation of ICI with chemotherapy appears to improve pathologic response rates in the resectable setting; however, longer term follow up is needed to confirm a survival benefit from this approach.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
